Case reportDiffuse panbronchiolitis: efficacy of low-dose erythromycin
References (10)
- et al.
Diffuse panbronchiolitis
A disease of the transitional zone of the lung
Chest
(1983) - et al.
Neutrophilia in bronchoalveolar lavage fluid of diffuse panbronchiolitis
Chest
(1990) - et al.
Diffuse panbronchiolitis observed in an Italian
Chest
(1990) Diffuse panbronchiolitis
Chest
(1991)- et al.
Diffuse panbronchiolitis: evaluation with high-resolution CT
Radiology
(1988)
Cited by (31)
Clinical efficacy of roxithromycin in men with chronic prostatitis/chronic pelvic pain syndrome in comparison with ciprofloxacin and aceclofenac: A prospective, randomized, multicenter pilot trial
2014, Journal of Infection and ChemotherapyCitation Excerpt :Since the 1950s, there has been growing evidence that macrolide antibiotics exert anti-inflammatory properties in lung diseases such as asthma [17]. Long-term treatment with macrolides dramatically increases survival in patients with diffuse panbronchiolitis, a disease with many similarities to cystic fibrosis [18–22]. Recently, roxithromycin was found to modulate mast cell activation, thereby possibly alleviating chronic inflammation [11].
The Role of Azithromycin in Patients with Cystic Fibrosis
2010, Paediatric Respiratory ReviewsCitation Excerpt :Dr Harry Shwachman 1950s1 In the last 50 years since Dr Shwachman's astute observation, there has been growing evidence to suggest that macrolide antibiotics have anti-inflammatory properties with beneficial effects in lung diseases such as asthma, diffuse pan-bronchiolitis, bronchiectasis and cystic fibrosis (CF).2–5 Several putative mechanisms of actions have been suggested, but a definitive one is yet to be proven.
Neutrophil survival-enhancing activity in sputum from patients with diffuse panbronchiolitis
2005, Respiratory MedicineThe effect of long-term treatment with erythromycin on Th1 and Th2 cytokines in diffuse panbronchiolitis
2004, Biochemical and Biophysical Research CommunicationsCitation Excerpt :Nearly 50% of the untreated patients have died within five years of diagnosis and for a long time, the long-term prognosis of DPB was poor. However, this once dismal outcome has been improved by the introduction of long-term treatment with low dose macrolide [8,9]. While the exact mechanisms are unknown, the anti-inflammatory rather than antimicrobial properties of macrolides seem to be responsible for the beneficial effects in patients with DPB.
Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis
2003, Respiratory MedicineDiffuse panbronchiolitis in Latin America
2000, American Journal of the Medical Sciences